The immunopeptidome represents the entirety of peptides presented by nucleated cells on HLA or MHC Class-I and Class-II proteins involved in the antigen-presentation pathway. It is essential in defining immunogenic epitopes in cell-mediated and humoral responses. Characterizing the immunopeptidome will enable you to discover targets for personalized cancer immunotherapies, such as neoantigens from tumor-specific mutations or tumor-associated antigens. Furthermore, novel mRNA and peptide-based vaccines and cell-based therapies can be developed.
We perform immunopeptidomics with our optimized high-throughput pipeline offering reproducible identification and quantification from minimal sample material.
The service can be applied in large-scale studies and is ideal for researchers looking for a standalone solution that digs deep into what is unknown but ready to be discovered.
“Biognosys is a valued partner of Grey Wolf Therapeutics across all departments for our immunopeptidomics research. Their technology and expertise have allowed us to define a signature for ERAP1 and ERAP2 inhibition in cancer cells and translate this knowledge into a pharmacodynamic biomarker. Together with Biognosys, we have demonstrated for the first time that the antigen repertoire can be changed by ERAP1 inhibition in cancer patients (ASCO 2024). The transition to DIA proteomics, established at Biognosys, has transformed the dynamic range of the PD biomarker, allowing us to see even the smallest of changes in patients. The breadth and quality of the data has convinced us that Biognosys is an industry leader in immunopeptidomics.”
Kris Clark, Ph.D.,
Head of Biology, Grey Wolf Therapeutics
“We were really impressed at the depth of peptide identification for both HLA I and II complexes from a small amount of cancer patient tissue. Thanks to quantitative MS, we can link biological hypothesis to quantification of neoantigen of interest.”
Jonathan Woodsmith, Ph.D.,
VP Advanced Analytics and AI, Indivumed
Resources
Posters
EMITT-1: Proof-of-mechanism immunopeptidome (ImPD) effects at target PK exposure, in a phase 1 study of GRWD5769 (a first-in-class inhibitor of Endoplasmic Reticulum Aminopeptidase 1 [ERAP1]) in patients with solid malignancies
Poster presented in collaboration with Grey Wolf Therapeutics at ASCO 2024 (Chicago, IL)
READ MORE
Posters
DEVELOPMENT OF FIRST-IN-CLASS ERAP2 INHIBITORS TO MODULATE THE CANCER IMMUNOPEPTIDOME
Collaborator poster on immunopeptidomics presented at the SITC 2023
READ MORE
Presentations
An Optimized Workflow for Reproducible Identification and Quantification of Class I and Class II Immunopeptides from Minimal Sample Input
Presenter: Luca Räss Oral Presentation at ASMS 2021
READ MORE
Case Studies
Biognosys Immunopeptidome Profiling Solution for MHC Class I And Class II Neoantigens Discovery in Tumor Biopsies – Case Study
The case study elaborates on the latest study on lung cancer we performed with our high-throughput TrueDiscovery™ platform for immunopeptidome profiling from needle-sized biopsie [...]
READ MORE
Deliverables
The results are presented and discussed with you in a dedicated conference call and delivered electronically in PDF and Excel formats, as well as via our complimentary data exploration tool, Proteoverse™.
Executive Summary
Materials and Methods
(suitable for publication)Complete Data Matrix
a) Normalized data matrix of all quantified peptides/proteins
b) Peptide sequences and associates protein annotation
Data Analysis
a) Characteristics of the peptide inventory
b) Hierarchical clustering analysis
c) Statistical testing to identify differentially expressed immunopeptides
d) Peptide-based PCA
e) Possibility of in-depth analysis of PTMs
f) Custom analysis upon request
g) Complimentary access to Proteoverse
Sample types and depths
Immunopeptidome Profiling can be applied to human tissues and cultured cells. Only a limited amount of material is required: 25 million cells or 10-15 mg fresh frozen tissue.
Project management
Biognosys is committed to providing the best possible results to our customers at the fastest possible project turnaround time.
